Blueleaf

At Blueleaf, the combined company formed by NHG and Clinicare Supplies, we empower the success of care homes around the world through the passion of our people and smart solutions. Blueleaf provides one of the most comprehensive ranges of products and services - from consumables and equipment, to furniture and interior design.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

DIVERSE BIOTECH ANNOUNCES ORPHAN-DRUG DESIGNATION FOR TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA

Diverse Biotech | May 04, 2020

news image

Diverse Biotech, Inc. www.diversebiotech.com has announced the U.S. Food & Drug Administration (FDA) has granted an orphan-drug designation request for one of its investigational new therapies for treatment of newly diagnosed glioblastoma, in conjunction with standard treatment, following adjuvant combined chemo-radiation. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, (Orphan Drug Act) including tax credits for qualified clinical te...

Read More

MEDTECH

FLAMINGO THERAPEUTICS EXPANDS ALLIANCE WITH IONIS PHARMACEUTICALS TO DEVELOP RNA-TARGETED THERAPIES FOR ONCOLOGY

Flamingo Therapeutics, Inc. | September 09, 2021

news image

Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer. This alliance is an expansion of an existing collaboration with Ionis on the FLAME™ discovery engine, following Flamingo's Series A financing in 2020. The agreement and discovery alliance will leverage Flamingo's de...

Read More

CELL AND GENE THERAPY

EVONETIX DEMONSTRATES NOVEL ENZYMATIC DNA SYNTHESIS METHOD

EVONETIX LTD | March 02, 2022

news image

EVONETIX LTD the synthetic biology company bringing semiconductor technology to DNA synthesis, announced it has achieved enzymatic DNA synthesis capability with its proprietary, thermally controlled synthesis chemistry. The culmination of a three-year development program, supported by Innovate UK and in collaboration with Durham University, the results demonstrate that Evonetix’s unique, semiconductor array-based platform is compatible with both chemical and enzymatic DNA synthesis, enabli...

Read More

CELL AND GENE THERAPY

AGEX THERAPEUTICS RECEIVES STOCK EXCHANGE DEFICIENCY LETTER

AgeX Therapeutics | November 24, 2021

news image

AgeX Therapeutics , Inc. a biotechnology company developing therapeutics for human aging and regeneration, announced that on November 17, 2021 it received a letter from the staff of the NYSE American indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses d...

Read More
news image

DIVERSE BIOTECH ANNOUNCES ORPHAN-DRUG DESIGNATION FOR TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA

Diverse Biotech | May 04, 2020

Diverse Biotech, Inc. www.diversebiotech.com has announced the U.S. Food & Drug Administration (FDA) has granted an orphan-drug designation request for one of its investigational new therapies for treatment of newly diagnosed glioblastoma, in conjunction with standard treatment, following adjuvant combined chemo-radiation. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, (Orphan Drug Act) including tax credits for qualified clinical te...

Read More
news image

MEDTECH

FLAMINGO THERAPEUTICS EXPANDS ALLIANCE WITH IONIS PHARMACEUTICALS TO DEVELOP RNA-TARGETED THERAPIES FOR ONCOLOGY

Flamingo Therapeutics, Inc. | September 09, 2021

Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer. This alliance is an expansion of an existing collaboration with Ionis on the FLAME™ discovery engine, following Flamingo's Series A financing in 2020. The agreement and discovery alliance will leverage Flamingo's de...

Read More
news image

CELL AND GENE THERAPY

EVONETIX DEMONSTRATES NOVEL ENZYMATIC DNA SYNTHESIS METHOD

EVONETIX LTD | March 02, 2022

EVONETIX LTD the synthetic biology company bringing semiconductor technology to DNA synthesis, announced it has achieved enzymatic DNA synthesis capability with its proprietary, thermally controlled synthesis chemistry. The culmination of a three-year development program, supported by Innovate UK and in collaboration with Durham University, the results demonstrate that Evonetix’s unique, semiconductor array-based platform is compatible with both chemical and enzymatic DNA synthesis, enabli...

Read More
news image

CELL AND GENE THERAPY

AGEX THERAPEUTICS RECEIVES STOCK EXCHANGE DEFICIENCY LETTER

AgeX Therapeutics | November 24, 2021

AgeX Therapeutics , Inc. a biotechnology company developing therapeutics for human aging and regeneration, announced that on November 17, 2021 it received a letter from the staff of the NYSE American indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses d...

Read More